Want to see IN:METROPOLIS full AI Analyst Report?
METROPOLIS Stock Chart & Stats
₹1929.70
-₹8.50(-0.42%)
At close: 4:00 PM EST
₹1929.70
-₹8.50(-0.42%)
Day’s Range― - ―
52-Week Range₹413.00 - ₹608.95
Previous CloseN/A
Volume139.28K
Average Volume (3M)3.90K
Market Cap
₹120.82B
Enterprise Value₹90.16K
Total Cash (Recent Filing)₹2.03B
Total Debt (Recent Filing)₹2.32B
Price to Earnings (P/E)63.5
Beta0.63
Next Earnings
Nov 10, 2026EPS Estimate
321.83Next Dividend Ex-DateN/A
Dividend Yield0.34%
Share Statistics
EPS (TTM)9.18
Shares Outstanding207,331,970
10 Day Avg. Volume4,604
30 Day Avg. Volume3,901
Financial Highlights & Ratios
PEG Ratio1.58
Price to Book (P/B)5.93
Price to Sales (P/S)5.45
P/FCF Ratio30.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)13.66
Revenue Forecast (FY)₹18.95B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMaterial de‑leveraging through FY2025 and steady equity growth provide durable capitalization. Lower leverage supports financial flexibility to fund network expansion, M&A or absorb shocks without immediate refinancing pressure, strengthening long-term solvency and strategic optionality.
Strong Cash GenerationConsistent positive operating and rising free cash flow, including a notable FY2026 step‑up, underpin durable self‑funding capacity. Robust FCF supports reinvestment in labs, working capital needs, debt paydown and potential shareholder returns without reliance on external financing.
Re-accelerating Revenue GrowthA return to mid‑teens revenue growth suggests strengthening market demand and utilization of the lab network. Sustained top‑line momentum can drive scale economies, improve per‑test margins over time and support higher absolute profit and cash generation if maintained.
Bears Say
Earnings And Margin VolatilityInconsistent operating profit and earnings quality reduce predictability of long‑term profitability. Even with revenue growth, margins have swung, implying cost, mix or efficiency issues that could limit sustainable margin expansion and complicate forecasting and capital allocation decisions.
Cash Conversion VariabilityUneven cash conversion driven by working‑capital timing reduces reliability of free cash flow despite positive aggregates. That variability can constrain funding for capex or network growth, elevate short‑term liquidity risk in downturns, and complicate dividend or buyback planning.
Debt Tick-up In FY2026An increase in debt in FY2026, even from a low base, narrows financial headroom. If indebtedness continues to rise it could raise interest costs and reduce flexibility for strategic investments or buffering against demand shocks, making future capital decisions more constrained.
Metropolis Healthcare Ltd. News
METROPOLIS FAQ
What was Metropolis Healthcare Ltd.’s price range in the past 12 months?
Metropolis Healthcare Ltd. lowest stock price was ₹413.00 and its highest was ₹608.95 in the past 12 months.
What is Metropolis Healthcare Ltd.’s market cap?
Metropolis Healthcare Ltd.’s market cap is ₹120.82B.
When is Metropolis Healthcare Ltd.’s upcoming earnings report date?
Metropolis Healthcare Ltd.’s upcoming earnings report date is Nov 10, 2026 which is in 98 days.
How were Metropolis Healthcare Ltd.’s earnings last quarter?
Metropolis Healthcare Ltd. released its earnings results on Aug 04, 2026. The company reported ₹2.7 earnings per share for the quarter, beating the consensus estimate of ₹2.677 by ₹0.023.
Is Metropolis Healthcare Ltd. overvalued?
According to Wall Street analysts Metropolis Healthcare Ltd.’s price is currently Overvalued.
Does Metropolis Healthcare Ltd. pay dividends?
Metropolis Healthcare Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.34%. See more information on Metropolis Healthcare Ltd. dividends here
What is Metropolis Healthcare Ltd.’s EPS estimate?
Metropolis Healthcare Ltd.’s EPS estimate is 321.83.
How many shares outstanding does Metropolis Healthcare Ltd. have?
Metropolis Healthcare Ltd. has 207,331,970 shares outstanding.
What happened to Metropolis Healthcare Ltd.’s price movement after its last earnings report?
Metropolis Healthcare Ltd. reported an EPS of ₹2.7 in its last earnings report, beating expectations of ₹2.677. Following the earnings report the stock price went up 0.018%.
Which hedge fund is a major shareholder of Metropolis Healthcare Ltd.?
Currently, no hedge funds are holding shares in IN:METROPOLIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Metropolis Healthcare Ltd.
Metropolis Healthcare Limited functions as a prominent diagnostic service provider throughout India. The company delivers a comprehensive array of clinical laboratory testing, specialized diagnostic profiles, and associated support services. Its capabilities span diverse medical fields, encompassing oncology, neurology, gynecology, and nephrology. Furthermore, Metropolis offers a variety of health check-up packages specifically tailored for different demographic groups, including men, women, senior citizens, youth, and corporate clients. These tests are vital for disease prediction, early identification, diagnostic screening, confirmation, and continuous monitoring. Beyond its core diagnostic offerings, the company also extends its expertise to corporate wellness programs, hospital laboratory management solutions, and clinical research. As of March 31, 2022, Metropolis had established an extensive network comprising 171 clinical laboratories, 9,000 sample collection points, and 704 assisted referral centers. Founded in 1980, the company's corporate headquarters are situated in Mumbai, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―
Vimta Labs Limited
―